We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brian Lane MD, PhD

Brian Lane MD, PhD

Chief, Spectrum Health Medical Group – Urology, Associate Professor, Michigan State University, Betz Family Endowed Chair for Cancer Research, Spectrum Health Cancer Center, Grand Rapids, MI

Dr. Brian Lane is a urologic oncologist specializing in kidney and prostate cancer. His current roles include Medical Director, Urologic Oncology Research, Spectrum Health Cancer Center and Professor in the Department of Surgery at Michigan State University College of Human Medicine. He has also served as Chief of Urology and Physician Lead of the Robotic and Advanced Minimally Invasive Surgery Program within Spectrum Health.  He completed the MD/PhD program at University of Michigan and residency in Urology and fellowship in Urologic Oncology at Cleveland Clinic.  Dr. Lane has served as an American Urologic Association (AUA) Foundation Scholar and member of the AUA Guidelines Committee for Renal Mass and Localized Renal Cancer.  Dr. Lane is Program Director for the Michigan Urological Surgery Improvement Collaborative (MUSIC) KIDNEY initiative, a physician-led quality improvement collaborative comprised of about 90% of urologists in the state of Michigan. He has performed more than 1000 nephrectomies, 850 radical prostatectomies, and 150 cystectomies; and over 1700 laparoscopic surgeries, including 1300 using the Da Vinci robot.  His primary research interests include outcomes in kidney cancer and prostate cancer.  He has authored more than 250 peer-reviewed publications in urologic oncology.

Disclosures

Dr. Lane has no disclosures.